Wen-Zhuo He (Wenzhuo He)

Publication Activity (10 Years)

Years Active: 2020-2023
Publications (10 Years): 5

Top Topics

Metastatic Colorectal Cancer

Advanced Non Small Cell Lung Cancer

Epidermal Growth Factor Receptor

Multidrug Resistant

Top Venues

Cancer medicine

Proceedings of the National Academy of Sciences of the United States of America

Current oncology (Toronto, Ont.)

Nature metabolism

This page only lists publications with an associated author ORCID identifier.

Publications

Chenran Wang, Maohua Huang, Yuning Lin, Yiming Zhang, Jing-Hua Pan, Chang Jiang, Minjing Cheng, Shenrong Li, Wen-Zhuo He, Zhengqiu Li, Zhengchao Tu, Jun Fan, Huhu Zeng, Jiahui Lin, Yongjin Wang, Nan Yao, Tongzheng Liu, Qi Qi, Xiangning Liu, Zhi-Min Zhang, Minfeng Chen, Liang-Ping Xia, Dongmei Zhang, Wen-Cai Ye
ENO2-derived phosphoenolpyruvate functions as an endogenous inhibitor of HDAC1 and confers resistance to antiangiogenic therapy. Nature metabolism (2023)
Wen-Zhuo He, Lei Wang, Chen-Xi Yin, Jia-Hong Yi, Ya-Nan Jin, Chang Jiang, Gui-Fang Guo, Liang-Ping Xia
Regorafenib with or without a programmed cell death protein 1 antibody as third-line treatment for microsatellite stable metastatic colorectal cancer. Cancer medicine (2022)
Yuan-Zhong Yang, Wan-Ming Hu, Liang-Ping Xia, Wen-Zhuo He
Association between somatic RET mutations and clinical and genetic characteristics in patients with metastatic colorectal cancer. Cancer medicine (2021)
Jinye Xie, Liang-Ping Xia, Wei Xiang, Wen-Zhuo He, Haofan Yin, Fang Wang, Tianxiao Gao, WeiWei Qi, Zhonghan Yang, Xia Yang, Ti Zhou, Guoquan Gao
Metformin selectively inhibits metastatic colorectal cancer with the KRAS mutation by intracellular accumulation through silencing MATE1. Proceedings of the National Academy of Sciences of the United States of America 117 (23) (2020)
Qi Quan, Yixing Wang, Fenghua Wang, Dongsheng Zhang, Xiuxing Chen, Wen-Zhuo He, Bei Zhang, Guifang Guo
Real World First-Line Treatments and Outcomes of Nab-Paclitaxel Plus Gemcitabine, mFOLFIRINOX and GEMOX in Unresectable Pancreatic Cancer from a Chinese Single Institution. Current oncology (Toronto, Ont.) 28 (1) (2020)